Dr. Carl Popelas is a pharmacist who is specialized in Oncology in Milford, Delaware. Patients can reach him at 21 W Clarke Ave, Milford or contact him on 302-430-5447. Active license number of Dr. Carl Popelas is A1-0003212 for Oncology in Delaware. Dr. Carl Popelas is a licensed pharmacist who has demonstrated specialized knowledge and skill in developing, recommending, implementing, monitoring, and modifying pharmacotherapeutic plans to optimize outcomes in patients with malignant diseases.
Complete Profile:
Dr. Carl Popelas speciality, credentials, practice address, contact phone number and fax are as below. Patients can call on the below given phone number for enquiries.
Name:
Dr. Carl Popelas
Specialization:
Oncology
Credentials:
PHARM.D.
Gender:
Male
Location:
21 W Clarke Ave, Milford, Delaware, 19963-1840
Phone:
302-430-5447
Fax:
302-430-5514
Professional Identification Codes:
NPI number stands for National Provider Identifier which is a unique 10-digit identification number issued to health care providers in the United States by the Centers for Medicare and Medicaid Services (CMS).
NPI details of Dr. Carl Popelas are as mentioned below.
NPI Number:
1386884989
NPI Enumeration Date:
23 Feb, 2009
NPI Last Update On:
23 Feb, 2009
Medical Licenses:
Pharmacists can have one or more medical licenses for different specialities in the same state or different states. Related medical licenses for Dr. Carl Popelas are as mentioned below.
Specialization
License Number
State
Status
Oncology
A1-0003212
Delaware
Primary
Business Mailing Address:
Business mailing address can be used for mailing purpose only, for visiting purpose patients need to refer above mentioned address.
Address:
21 W Clarke Ave, Milford, Delaware
Zip:
19963-1840
Phone Number:
302-430-5447
Fax Number:
302-430-5514
Patients can reach Dr. Carl Popelas at 21 W Clarke Ave, Milford, Delaware or can call on phone at 302-430-5447.
Comments/ Reviews:
*Data of this site is collected from Medicare & Medicaid Services (CMS) and NPPES. Last updated on 09 December, 2024.